Pulmonary Embolism Prevalence in Hospitalized Patients With COPD
Patients with COPD who were hospitalized for acutely worsening respiratory symptoms had a prevalence of pulmonary embolism of 5.9%.
Patients with COPD who were hospitalized for acutely worsening respiratory symptoms had a prevalence of pulmonary embolism of 5.9%.
Reference equations to predict forced expiratory flow values adjusted for forced vital capacity resulted in lower sample variability.
Duration-dependent beneficial effects of metformin, sulfonylurea, and thiazolidinedione use on COPD exacerbation have been observed in patients with COPD and diabetes.
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate may reduce the risk of death compared with glycopyrrolate/formoterol fumarate in patients with COPD.
The prevalence of chronic neck pain and chronic low back pain has been shown to be higher in patients with COPD compared with individuals without COPD.
An analysis of real-world data demonstrated that patients taking fluticasone propionate-salmeterol for COPD had outcomes that closely matched results of randomized controlled trials.
Patients with chronic obstructive pulmonary disease showed lasting improvements for up to 2 years in anxiety and quality of life following 8 weeks of pulmonary rehabilitation.
Use of the novel composite end point known as COPDCompEx may be able to predict treatment effect on moderate to severe exacerbations of COPD, thus allowing shorter phase 2 clinical trials requiring fewer patients compared with current studies.
Fluticasone/salmeterol and budesonide/formoterol are common treatments for COPD; researchers investigated whether these treatments may be correlated with active tuberculosis risk.
Pulmonary hypertension is associated with higher in-hospital mortality, morbidity, length of stay, and health care utilization in patients admitted to the hospital with an acute exacerbation of COPD.